The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a new drug application (NDA) for its investigational single-tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) to the US Food and Drug Administration (FDA), to treat pulmonary arterial hypertension (PAH).

The company is seeking approval for the combination therapy for the long-term treatment of PAH in adult patients with World Health Organisation functional class II-III.

Tadalafil is a phosphodiesterase type 5 inhibitor intended to treat PAH (WHO Group I) to enhance exercise ability, while Opsumit (macitentan) is a prescription medicine.

Janssen has submitted the NDA based on positive data from the Phase III A DUE trial, which achieved its primary endpoint.

The randomised, multi-centre, double-blind, active-controlled and adaptive parallel group trial compared the safety and efficacy of investigational M/T STCT against macitentan and tadalafil monotherapies in PAH patients.

It demonstrated that the combination therapy had a significant positive impact on pulmonary haemodynamics compared to the individual treatments of macitentan and tadalafil in patients with PAH.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Janssen research and development global therapeutic area head Dr James List stated: “People with PAH are often prescribed numerous medicines to manage their condition, so the potential to offer a single tablet combination of two guideline-recommended therapies could not only decrease pill burden but may also help improve the patient treatment experience and clinical outcomes.

“Today’s submission builds on our decades-long commitment to address patient needs and bring forward medicines with the potential to offer an improved standard of PAH care.”